The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| LIAN | -75.86% | N/A | N/A | +5% |
| S&P | +14.5% | +93.32% | +14.09% | +45% |
LianBio operates as a biopharmaceutical company, which engages in the development and commercialization of medicines for patients with unmet medical needs. It develops a portfolio of clinically validated product candidates for cardiovascular, oncology, ophthalmology, inflammatory disease, and respiratory indications. The company was founded by Konstantin Poukalov on July 17, 2019 and is headquartered in Princeton, NJ.
LianBio stock is seeing explosive gains, and it's one of this week's biggest winners.
Investors are loving LianBio's new deal with Bristol Myers Squibb.
| Q4 2023 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.35M | 0.0% |
| Market Cap | $18.24M | 0.0% |
| Net Income | $383.73M | 0.0% |
| EBITDA | -$22.12M | 0.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2023 | YOY Change | |
|---|---|---|
| Net Cash | $438.58M | 0.0% |
| Inventory | 0 | 0.0% |
| Q4 2023 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.51M | 0.0% |
| Short Term Debt | $1.95M | 0.0% |
| Q4 2023 | YOY Change | |
|---|---|---|
| Return On Assets | 67.02% | 0.0% |
| Return On Invested Capital | -55.68% | 0.0% |
| Q4 2023 | YOY Change | |
|---|---|---|
| Free Cash Flow | $311.38M | 0.0% |
| Operating Free Cash Flow | $311.52M | 0.0% |
| Metric | Q4 2023 | YoY Change |
|---|---|---|
| Price to Earnings | 1.53 | - |
| Price to Book | 0.09 | - |
| Price to Tangible Book Value | 0.09 | - |
| Price to Free Cash Flow TTM | 1.87 | - |
| Enterprise Value to EBITDA | 3.69 | - |
| Free Cash Flow Yield | 53.5% | - |
| Return on Equity | 74.7% | - |
| Total Debt | $2.46M | - |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
